 |
|
Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
Kyung-Soo Kim, Byung-Wan Lee
Clin Mol Hepatol. 2020;26(4):430-443. Published online 2020 Aug 14 DOI: https://doi.org/10.3350/cmh.2020.0137
|
|
Citations to this article as recorded by
 The Triad of Risk: Linking MASLD, Cardiovascular Disease and Type 2 Diabetes; From Pathophysiology to Treatment
Eleni Michalopoulou, John Thymis, Stamatios Lampsas, George Pavlidis, Konstantinos Katogiannis, Dimitrios Vlachomitros, Eleni Katsanaki, Gavriella Kostelli, Sotirios Pililis, Loukia Pliouta, Aikaterini Kountouri, Ioannis S. Papanikolaou, Vaia Lambadiari,
Journal of Clinical Medicine.2025; 14(2): 428. CrossRef Deciphering significances of autophagy in the development and metabolism of adipose tissue
Zitao Liu, Haoyuan Peng, Pengfei Liu, Feiyi Duan, Yutian Yang, Pengkun Li, Zhihao Li, Jiaoyan Wu, Jiayi Chang, Dandan Shang, Qiwen Tian, Jiawei Zhang, Yucheng Xie, Zhenzhen Liu, Yang An
Experimental Cell Research.2025; 446(2): 114478. CrossRef Treatment with a new barbituric acid derivative suppresses diet-induced metabolic dysfunction and non-alcoholic fatty liver disease in mice
Fat-Moon Suk, Fang-Yu Hsu, Ming-Hua Hsu, Wan-Chun Chiu, Cheng-Chieh Fang, Tzu-Lang Chen, Yi-Jen Liao
Life Sciences.2024; 336: 122327. CrossRef Metabolic Associated Fatty Liver Disease in Children and Adolescents:
Mechanisms of a Silent Epidemic and Therapeutic Options
Antonella Mosca, Luca Della Volpe, Maria Rita Sartorelli, Donatella Comparcola, Silvio Veraldi, Anna Alisi, Giuseppe Maggiore
Current Pediatric Reviews.2024; 20(3): 296. CrossRef Effect of ipragliflozin on liver enzymes in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
Rizwana Parveen, Shadan Hussain, Sparsh Saini, Parvej Khan, Nilanjan Saha, Nidhi
Expert Opinion on Pharmacotherapy.2024; 25(7): 925. CrossRef The Efficacy of Empagliflozin in Combination with Pioglitazone on the Improvement of Fatty Liver Disease in Patients with Type 2 Diabetes
Morteza Aghajanpoor, Mehrzad Gholampourdehaki, Reza Mosaed, Iraj Mirzaii-Dizgah, Afsaneh Vosughi
Annals of Military and Health Sciences Research.2024;[Epub] CrossRef The gut-liver axis: emerging mechanisms and therapeutic approaches for nonalcoholic fatty liver disease and type 2 diabetes mellitus
Monika Bhardwaj, Papiya Mitra Mazumder
Naunyn-Schmiedeberg's Archives of Pharmacology.2024; 397(11): 8421. CrossRef NAFLD-associated hepatocellular carcinoma (HCC) – A compelling case for repositioning of existing mTORc1 inhibitors
Nutan Sharma, Lakhwinder Singh, Aditya Sharma, Ajay Kumar, Dinesh Mahajan
Pharmacological Research.2024; 208: 107375. CrossRef Regulation mechanism of endoplasmic reticulum stress on metabolic enzymes in liver diseases
Shaojun Zhou, Kaiwen Cheng, Yi Peng, Yuxi Liu, Qingqing Hu, Su Zeng, Xuchen Qi, Lushan Yu
Pharmacological Research.2024; 207: 107332. CrossRef Effects of Propolis Consumption on Glycemic Indices and Liver Enzymes in Adults: A Grading of Recommendations Assessment, Development, and Valuation-assessed Systematic Review and Dose-Response Meta-analysis
Shaghayegh Adeli, Mahsa Maroofi, Fatemeh Pourteymour Fard Tabrizi, Beitullah Alipour, Marzieh Heidari, Mahdi Vajdi, Mahdieh Abbasalizad-Farhangi
Clinical Therapeutics.2024; 46(9): e6. CrossRef Hepatocentric approach to achieving compensation of diabetes mellitus in people with non-alcoholic steatohepatitis
N.M. Protas, I.O. Kostitska, M.V. Bielinskyi
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2024; 20(5): 375. CrossRef Drivers of cardiovascular disease in metabolic dysfunction-associated steatotic liver disease: the threats of oxidative stress
Erika T. Minetti, Naomi M. Hamburg, Reiko Matsui
Frontiers in Cardiovascular Medicine.2024;[Epub] CrossRef The impact of vildagliptin as an add‐on therapy on matrix metalloproteinase‐14 levels, liver stiffness and subclinical atherosclerosis in adolescents with type 1 diabetes and non‐alcoholic steatohepatitis: A randomized controlled trial
Zeinab Anwar ElKabbany, Eman Abdel Rahman Ismail, Eman Tawfik Hamed, Nancy Samir Elbarbary
Diabetes, Obesity and Metabolism.2024; 26(12): 5857. CrossRef Reply to correspondence on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis”
Tian-Yi Ren, Mohammed Eslam, Jian-Gao Fan
Clinical and Molecular Hepatology.2024; 30(4): 1039. CrossRef Letter: Filling the Gaps—Enhancing MASLD Prognosis With Imaging, Diverse Populations and Extended Follow‐Up
Qi‐En Shen, Chengfu Xu
Alimentary Pharmacology & Therapeutics.2024; 60(11-12): 1662. CrossRef Vitamin E and Pioglitazone: A Comprehensive Systematic Review of Their Efficacy in Non-alcoholic Fatty Liver Disease
Iqra J Mazhar, Mohamed Yasir, Saba Sarfraz, Gandhala Shlaghya, Sri Harsha Narayana, Ujala Mushtaq, Basim Shaman Ameen, Chuhao Nie, Daniel Nechi, Sai Sri Penumetcha
Cureus.2023;[Epub] CrossRef Development and prognosis of hepatocellular carcinoma in patients with diabetes
Takuma Nakatsuka, Ryosuke Tateishi
Clinical and Molecular Hepatology.2023; 29(1): 51. CrossRef Correspondence on Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”
Seung Min Lee, Dae Won Jun
Clinical and Molecular Hepatology.2023; 29(1): 171. CrossRef Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials
Jihyun An, Joo Hyun Sohn
Clinical and Molecular Hepatology.2023; 29(Suppl): S268. CrossRef Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
Asako Nogami, Masato Yoneda, Michihiro Iwaki, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa, Kento Imajo, Satoru Saito, Atsushi Nakajima
Clinical and Molecular Hepatology.2023; 29(Suppl): S123. CrossRef Linalool Mitigated High-Fat Diet–Induced Non-alcoholic Fatty Liver Disease by Regulating the Intestinal-Hepatic Axis via TGF-β/NF-kB/TLR4/ZO-1 Pathway
Tamilmani Periyasamy, V. V. Sathibabu Uddandrao, Chandrasekaran Ponnusamy, Saravanan Ganapathy, Sethumathi Ponnusamy Pudhupalayam, Sengottuvelu Singaravel, Ponmurugan Ponnusamy, Jagadeesan Ramasamy, Kalaivani Aiyasamy, Vadivukkarasi Sasikumar
Revista Brasileira de Farmacognosia.2023; 33(3): 617. CrossRef The seamless integration of dietary plant-derived natural flavonoids and gut microbiota may ameliorate non-alcoholic fatty liver disease: a network pharmacology analysis
Ki-Kwang Oh, Haripriya Gupta, Raja Ganesan, Satya Priya Sharma, Sung-Min Won, Jin-Ju Jeong, Su-Been Lee, Min-Gi Cha, Goo-Hyun Kwon, Min-Kyo Jeong, Byeong-Hyun Min, Ji-Ye Hyun, Jung-A Eom, Hee-Jin Park, Sang-Jun Yoon, Mi-Ran Choi, Dong Joon Kim, Ki-Tae Suk
Artificial Cells, Nanomedicine, and Biotechnology.2023; 51(1): 217. CrossRef Malattia grassa del fegato: tra fattori ambientali e predisposizione genetica
Antonella Mosca, Giuseppe Maggiore
Medico e Bambino.2023; 42(6): 355. CrossRef E4orf1 improves adipose tissue-specific metabolic risk factors and indicators of cognition function in a mouse model of Alzheimer’s disease
Md Shahjalal Hossain Khan, Marleigh Hefner, Arubala Reddy, Nikhil V. Dhurandhar, Vijay Hegde
Nutrition & Diabetes.2023;[Epub] CrossRef Thiazolidinedione Use Is Associated with a Borderline Lower Risk of Multiple Myeloma and a Significantly Lower Risk of Death in Patients with Type 2 Diabetes Mellitus in Taiwan
Chin-Hsiao Tseng
Cancers.2023; 15(17): 4276. CrossRef Carbon Dots as Potential Therapeutic Agents for Treating Non-Alcoholic Fatty Liver Disease and Associated Inflammatory Bone Loss
Lei Huang, Qinzhu Bai, Zhuoran Wang, Xu Zhang, Kexuan Liu, Jing Cui, Liuyi Du, Shuchen Liu, Yunhe Fu, Huan Wang, Daowei Li, Hongchen Sun
Bioconjugate Chemistry.2023; 34(9): 1704. CrossRef Effect of dapagliflozin on liver and pancreatic fat in patients with type 2 diabetes and non-alcoholic fatty liver disease
Mengran Shi, Hao Zhang, Wei Wang, Xiao Zhang, Jiawei Liu, Qixian Wang, Yuan Wang, Chunlin Zhang, Xiaoqin Guo, Qiao Qiao, Chun Cui, Jing Xu, Jian Wang
Journal of Diabetes and its Complications.2023; 37(10): 108610. CrossRef Comparison of biochemical response during antiviral treatment in patients with chronic hepatitis B infection
Si Ho Kim, Eun Ju Cho, Boo‐ok Jang, Kyunghan Lee, Jae Kyun Choi, Gwang Hyeon Choi, Jeong‐Hoon Lee, Su Jong Yu, Yoon Jun Kim, Yun Bin Lee, Jeong‐Hwan Yoon, Jin‐Wook Kim, Sook‐Hyang Jeong, Eun Sun Jang
Liver International.2022; 42(2): 320. CrossRef Effectiveness and safety of teneligliptin added to patients with type 2 diabetes inadequately controlled by oral triple combination therapy: A multicentre, randomized, double‐blind, and placebo‐controlled study
Minyoung Lee, Woo‐je Lee, Jae Hyeon Kim, Byung‐Wan Lee
Diabetes, Obesity and Metabolism.2022; 24(6): 1105. CrossRef Liraglutide Exerts Protective Effects by Downregulation of PPARγ, ACSL1 and SREBP-1c in Huh7 Cell Culture Models of Non-Alcoholic Steatosis and Drug-Induced Steatosis
Tea Omanovic Kolaric, Tomislav Kizivat, Vjera Mihaljevic, Milorad Zjalic, Ines Bilic-Curcic, Lucija Kuna, Robert Smolic, Aleksandar Vcev, George Y. Wu, Martina Smolic
Current Issues in Molecular Biology.2022; 44(8): 3465. CrossRef Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD
Beom Kyung Kim, Nobuharu Tamaki, Kento Imajo, Masato Yoneda, Nancy Sutter, Jinho Jung, Tuo Lin, Xin M. Tu, Jaclyn Bergstrom, Khang Nguyen, Leyna Nguyen, Tracy Le, Egbert Madamba, Lisa Richards, Mark A. Valasek, Cynthia Behling, Claude B. Sirlin, Atsushi N
Journal of Hepatology.2022; 77(6): 1482. CrossRef Effect of metabolic dysfunction‐associated fatty liver disease on liver cancer risk in a population with chronic hepatitis B virus infection: A nationwide study
Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin‐Ha Yoon, Beom Kyung Kim
Hepatology Research.2022; 52(12): 975. CrossRef Tirzepatide: A novel, first-in-class, dual GIP/GLP-1 receptor agonist
Shasta Tall Bull, Wesley Nuffer, Jennifer M. Trujillo
Journal of Diabetes and its Complications.2022; 36(12): 108332. CrossRef Non-obese NAFLD had no better cardio-metabolic risk profile than obese NAFLD in type 2 diabetic patients
Ziyin Zhang, Lu Zhang, Wangyan Jiang, Tingting Du, Gang Yuan
Cardiovascular Diabetology.2022;[Epub] CrossRef To Do One and To Get More: Part II. Diabetes and metabolic dysfunction-associated fatty liver diseases
Wen-Ling Lee, Peng-Hui Wang, Szu-Ting Yang, Chia-Hao Liu, Wen-Hsun Chang, Fa-Kung Lee
Journal of the Chinese Medical Association.2022;[Epub] CrossRef Gut microbiota: The key to the treatment of metabolic syndrome in traditional Chinese medicine – a case study of diabetes and nonalcoholic fatty liver disease
Yang Bao, Xiao Han, Da Liu, Zhaolin Tan, Yongzhi Deng
Frontiers in Immunology.2022;[Epub] CrossRef DPP-4 Inhibitor in Type 2 Diabetes Mellitus Patient with Non-Alcoholic Fatty Liver Disease: Achieving Two Goals at Once?
Ji Cheol Bae
Endocrinology and Metabolism.2022; 37(6): 858. CrossRef Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE(-/-) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis
Narjes Nasiri-Ansari, Chrysa Nikolopoulou, Katerina Papoutsi, Ioannis Kyrou, Christos S. Mantzoros, Georgios Kyriakopoulos, Antonios Chatzigeorgiou, Vassiliki Kalotychou, Manpal S. Randeva, Kamaljit Chatha, Konstantinos Kontzoglou, Gregory Kaltsas, Athana
International Journal of Molecular Sciences.2021; 22(2): 818. CrossRef Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: Diagnosis and Treatment
Sook Jung Lee, Byung-Wan Lee
The Journal of Korean Diabetes.2021; 22(1): 38. CrossRef From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
Seong Hee Kang, Yuri Cho, Soung Won Jeong, Seung Up Kim, Jin-Woo Lee
Clinical and Molecular Hepatology.2021; 27(2): 257. CrossRef Efficacy of Various Hypoglycemic Agents in the Treatment of Patients With Nonalcoholic Liver Disease With or Without Diabetes： A Network Meta-Analysis
Jingxuan Lian, Jianfang Fu
Frontiers in Endocrinology.2021;[Epub] CrossRef Endoplasmic Reticulum Stress and Autophagy in the Pathogenesis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Evidence and Perspectives
Christina-Maria Flessa, Ioannis Kyrou, Narjes Nasiri-Ansari, Gregory Kaltsas, Athanasios G. Papavassiliou, Eva Kassi, Harpal S. Randeva
Current Obesity Reports.2021; 10(2): 134. CrossRef Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis
Jingxuan Lian, Jianfang Fu
Frontiers in Endocrinology.2021;[Epub] CrossRef Meta-analysis of trials in non-alcoholic fatty liver disease with therapeutic interventions for metabolic syndrome
Stewart G. Albert, Emily M. Wood
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2021; 15(5): 102232. CrossRef Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B
Hye Won Lee, Young Youn Cho, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Soo Young Park
Journal of Viral Hepatitis.2021; 28(11): 1570. CrossRef In a Prediabetic Model, Empagliflozin Improves Hepatic Lipid Metabolism Independently of Obesity and before Onset of Hyperglycemia
Martina Hüttl, Irena Markova, Denisa Miklankova, Iveta Zapletalova, Martin Poruba, Martin Haluzik, Ivana Vaněčkova, Hana Malinska
International Journal of Molecular Sciences.2021; 22(21): 11513. CrossRef Transcriptomic Analysis Reveals the Protective Effects of Empagliflozin on Lipid Metabolism in Nonalcoholic Fatty Liver Disease
Yuting Ma, Chengxia Kan, Hongyan Qiu, Yongping Liu, Ningning Hou, Fang Han, Junfeng Shi, Xiaodong Sun
Frontiers in Pharmacology.2021;[Epub] CrossRef Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated “enemy”?
Dimitrios Patoulias, Michael Doumas
Clinical and Molecular Hepatology.2020; 26(4): 582. CrossRef
|